StockNews.com upgraded shares of Ironwood Pharmaceuticals (NASDAQ:IRWD – Free Report) from a hold rating to a buy rating in a ...

The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the progression of fibrocalcific aortic valve stenosis in phase I and II studies.

NO then reacts with guanylate cyclase in vascular smooth muscle to produce cGMP that reduces intracellular calcium concentrations resulting in relaxation of vascular smooth muscle and consequent ...

More information: Bin Zhang et al, Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow ...

Intech Investment Management LLC boosted its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report) by 30.0% ...

Stephen, R., Palczewski, K., Sousa, M.C. (2008) Ca2+-dependent regulation of phototransduction. Photochem. And Photobiol. 84. 903-910 Stephen, R. (2008) Structural ...

A novel therapeutic showed significant promise in slowing aortic valve calcification, potentially extending time until or eliminating need for transcatheter or surgical intervention for stenosis, ...

Nitric oxide (iNO) is selective pulmonary vasodilation and is delivered to the patient via mechanical ventilation after dilution with an oxygen/air mixture nitric oxide delivery system. Nitric oxide ...